Mafalda Oliveira
YOU?
Author Swipe
View article: Endocrine-based strategies after CDK4/6 inhibitors in biomarker-selected subgroup of hormone receptor positive advanced breast cancer: A systematic review and network meta-analysis
Endocrine-based strategies after CDK4/6 inhibitors in biomarker-selected subgroup of hormone receptor positive advanced breast cancer: A systematic review and network meta-analysis Open
View article: PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with <i>PIK3CA</i> -Mutated Solid Tumors and in Preclinical Models
PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with <i>PIK3CA</i> -Mutated Solid Tumors and in Preclinical Models Open
Purpose: PIK3CA mutations frequently drive solid tumors, particularly hormone receptor–positive breast cancer. Inavolisib, an ATP-competitive p110α inhibitor, also promotes the degradation of mutated p110α. PI3K inhibitors have generally s…
View article: Phase Ib study of xentuzumab and abemaciclib in patients with advanced solid tumors and in combination with endocrine therapy in patients with advanced breast cancer
Phase Ib study of xentuzumab and abemaciclib in patients with advanced solid tumors and in combination with endocrine therapy in patients with advanced breast cancer Open
Xentuzumab + abemaciclib + ETs demonstrated manageable tolerability and promising efficacy, especially in patients with breast cancer and non-visceral metastases.
View article: Systematic Review On Ischemic Events And PostMyocardial Infarction Heart Failure: From Initial Approach To Definitive Treatment
Systematic Review On Ischemic Events And PostMyocardial Infarction Heart Failure: From Initial Approach To Definitive Treatment Open
Acute myocardial infarction (AMI) remains one of the leading causes of global morbidity and mortality, despite advances in diagnostic and treatment strategies. Among its complications, post-ischemic heart failure (HF) stands out as a clini…
View article: Table 2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Table 2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1 Open
AE profile for camizestrant in combination with abemaciclib, palbociclib, or ribociclib (irrespective of causality); AEs reported in ≥20% of patients.a
View article: Figure 2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Figure 2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1 Open
ORR, CBR24, and median PFS for (A) camizestrant in combination with abemaciclib, palbociclib, or ribociclib; (B) subgroup analysis pooled across all camizestrant + CDK4/6i combinations. NC is represented by an arro…
View article: Supplementary Figure S3 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Supplementary Figure S3 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1 Open
Abemaciclib, palbociclib, and ribociclib concentrations at steady state
View article: Supplementary Figure S1 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Supplementary Figure S1 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1 Open
CONSORT diagrams
View article: Figure 3 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Figure 3 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1 Open
ESR1m ctDNA dynamics for each CDK4/6i + camizestrant combination. (Top) waterfall plot showing percentage change in ESR1m summed VAF at C2D1 compared with C1D1 in each evaluable patient. (Middle) vector plot showing absolute …
View article: Supplementary Figure S4 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Supplementary Figure S4 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1 Open
ORR, CBR24, and median PFS for subgroup analysis across pooled camizestrant 75 mg combination arms
View article: Supplementary Table S1 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Supplementary Table S1 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1 Open
Study representativeness
View article: Data from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Data from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1 Open
Purpose:This trial investigated the safety and tolerability of camizestrant with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in women with estrogen receptor–positive, HER2− advanced breast cancer.Patients and Methods:SERENA-1 (NCT0361…
View article: Supplementary Figure S2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Supplementary Figure S2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1 Open
Time course of heart rate reductions and QTcF
View article: Supplementary Table S4 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Supplementary Table S4 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1 Open
Camizestrant PK parameters
View article: Table 1 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Table 1 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1 Open
Baseline characteristics and patient demographics for camizestrant in combination with abemaciclib, palbociclib, or ribociclib.
View article: Supplementary Figure S5 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Supplementary Figure S5 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1 Open
Percentage change in ESR1m variants
View article: Figure 1 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Figure 1 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1 Open
AEs leading to dose reduction or discontinuation in patients treated with camizestrant 75, 150, or 300 mg combined with either abemaciclib, palbociclib, or ribociclib. Description data are presented as number and % of patients. N, number; …
View article: Supplementary Table S3 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Supplementary Table S3 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1 Open
Adverse event profile for camizestrant
View article: Supplementary Table S2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Supplementary Table S2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1 Open
Safety summary of camizestrant
View article: Integrating Intestinal Ultrasound to Clinical Trials in Patients With Crohn’s Disease: Opportunities and Challenges
Integrating Intestinal Ultrasound to Clinical Trials in Patients With Crohn’s Disease: Opportunities and Challenges Open
This narrative review summarizes the current knowledge on using intestinal ultrasonography (IUS) to evaluate disease activity in patients with Crohn’s disease (CD) and explores its potential role in clinical trials. Current trial endpoints…
View article: Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial
Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial Open
These findings highlight the relevance of gene expression profiling in HER2-positive breast cancer and support biomarker-driven patient selection. Long-term PATRICIA results validate the potential of non-chemotherapy-based approaches in HR…
View article: Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1 Open
Purpose: This trial investigated the safety and tolerability of camizestrant with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in women with estrogen receptor–positive, HER2− advanced breast cancer. Patients and Methods: SERENA-1 (NCT0…
View article: A IMPORTÂNCIA DA MUSICALIZAÇÃO NO PROCESSO DE APRENDIZAGEM NA EDUCAÇÃO INFANTIL
A IMPORTÂNCIA DA MUSICALIZAÇÃO NO PROCESSO DE APRENDIZAGEM NA EDUCAÇÃO INFANTIL Open
O presente manuscrito tem como objetivo compreender a importância da musicalização no processo de aprendizagem de crianças da educação infantil. Desse modo, por meio de pesquisa bibliográfica, tematiza-se, num primeiro momento, o desenvolv…
View article: Associação entre microcefalia e alterações do neurodesenvolvimento em crianças diagnosticadas com a Síndrome Congênita do Zika (SCZ)
Associação entre microcefalia e alterações do neurodesenvolvimento em crianças diagnosticadas com a Síndrome Congênita do Zika (SCZ) Open
Objetivo: Investigar evidências das associações existentes entre a microcefalia e as alterações do neurodesenvolvimento em crianças expostas à infecção por Síndrome Congênita do Zika (SCZ). Métodos: Foi realizada uma revisão integrativa da…
View article: Mental Suffering of Servants at A Federal Higher Education Institution in Times of Pandemic
Mental Suffering of Servants at A Federal Higher Education Institution in Times of Pandemic Open
Objective: The study aims to analyze the mental health of employees at a federal higher education institution (IFES) during the COVID-19 pandemic. Theoretical Framework: With the worsening of COVID-19, some factors contribute to the increa…
View article: Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study
Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study Open
Inavolisib plus ET demonstrated a manageable safety profile and encouraging preliminary anti-tumour activity in patients with PIK3CA-mutated, HR-positive, HER2-negative LA/mBC, including those in the post-CDK4/6i setting.
View article: TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer
TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer Open
Background: Standard of care (SoC) for patients with advanced triple-negative breast cancer (TNBC) whose tumors express PD-L1 (combined positive score ⩾ 10) is chemotherapy plus anti-PD-(L)1 inhibitors; however, prognosis and survival for …
View article: Selective tubulin-binding drugs induce pericyte phenotype switching and anti-cancer immunity
Selective tubulin-binding drugs induce pericyte phenotype switching and anti-cancer immunity Open
View article: Sintomas musculoesqueléticos associados à COVID longa
Sintomas musculoesqueléticos associados à COVID longa Open
Objetivo: Revisar evidências acerca dos sintomas musculoesqueléticos associados à COVID longa, com o intuito de compreender sua repercussão na população afetada. Métodos: Foi sistematizada uma revisão integrativa de literatura nas bases de…
View article: Identifying germline pathogenic variants in breast cancer using tumor sequencing
Identifying germline pathogenic variants in breast cancer using tumor sequencing Open